The New Zealand Black Mouse as a Model for the Development and Progression of Chronic Lymphocytic Leukemia

被引:12
|
作者
Salerno, Erica [1 ]
Yuan, Yao [1 ]
Scaglione, Brian J. [1 ,2 ]
Marti, Gerald [3 ]
Jankovic, Alexander [3 ]
Mazzella, Fermina [1 ]
Laurindo, Maria Fernanda [1 ]
Despres, Daryl [4 ]
Baskar, Sivasubramanian [5 ]
Rader, Christoph [5 ]
Raveche, Elizabeth [1 ]
机构
[1] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Lab Med & Pathol, Newark, NJ 07103 USA
[2] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA
[3] US FDA, Ctr Biol Evaluat & Res, NIH, Bethesda, MD 20892 USA
[4] NINDS, Mouse Imaging Facil, NIH, Bethesda, MD 20892 USA
[5] NCI, NIH, Bethesda, MD 20892 USA
关键词
chronic lymphocytic leukemia; monoclonal B cell lymphocytosis; miR-16; murine model of CLL; New Zealand Black; side population; B-CELL LYMPHOCYTOSIS; SIDE POPULATION; STEM-CELLS; CLL; GENES; CANCER; 13Q14; RNA; IDENTIFICATION; MICRORNA-16;
D O I
10.1002/cyto.b.20544
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Similar to a subset of human patients who progress from monoclonal B lymphocytosis (MBL) to chronic lymphocytic leukemia (CLL), New Zealand Black (NZB) mice have an age-associated progression to CLL. The murine disease is linked to a genetic abnormality in microRNA mir-15a/16-1 locus, resulting in decreased mature miR-15a/16. Methods: Spleens of aging NZB were analyzed for the presence of B-1 cells via flow cytometry and for the presence of a side population (SP) via the ability of cells to exclude Hoechst 33342 dye. The SP was assayed for the presence of hyperdiploid B-1 clones and for the ability to differentiate into B-1 cells in vitro and transfer disease in vivo. In addition, enhanced apoptosis of chemoresistant NZB B-1 cells was examined by restoring miR-16 levels in nutlin-treated cells. Results: Aging NZB mice develop a B-1 expansion and clonal development that evolves from MBL into CLL. An expansion in SP is also seen. Although the SP did contain increased cells with stem cell markers, they lacked malignant B-1 cells and did not transfer disease in vivo. Similar to B-1 cells, splenic NZB SP also has decreased miR-15a/16 when compared with C57BI/6. Exogenous addition of miR15a/16 to NZB B-1 cells resulted in increased sensitivity to nutlin. Conclusion: NZB serve as an excellent model for studying the development and progression of age-associated CLL. NZB SP cells do not seem to contain cancer stem cells, but rather the B-1 stem cell. NZB B-1 chemoresistance may be related to reduced miR-15a/16 expression. (C) 2010 International Clinical Cytometry Society
引用
收藏
页码:S98 / S109
页数:12
相关论文
共 50 条
  • [21] Role of microRNA in chronic lymphocytic leukemia onset and progression
    Veronica Balatti
    Yuri Pekarky
    Carlo M Croce
    Journal of Hematology & Oncology, 8
  • [22] New treatments for chronic lymphocytic leukemia
    Chanan-Khan A.A.
    Current Oncology Reports, 2007, 9 (5) : 353 - 360
  • [23] Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model
    Lascano, Valeria
    Guadagnoli, Marco
    Schot, Jan G.
    Luijks, Dieuwertje M.
    Guikema, Jeroen E. J.
    Cameron, Katherine
    Hahne, Michael
    Pals, Steven
    Slinger, Erik
    Kipps, Thomas J.
    van Oers, Marinus H. J.
    Eldering, Eric
    Medema, Jan Paul
    Kater, Arnon P.
    BLOOD, 2013, 122 (24) : 3960 - 3963
  • [24] New Agents in Chronic Lymphocytic Leukemia
    Thomas S. Lin
    Current Hematologic Malignancy Reports, 2010, 5 : 29 - 34
  • [25] New Therapies for Chronic Lymphocytic Leukemia
    Robak, Pawel
    Robak, Tadeusz
    CURRENT CANCER THERAPY REVIEWS, 2013, 9 (04) : 245 - 257
  • [26] New Agents in Chronic Lymphocytic Leukemia
    Lin, Thomas S.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2010, 5 (01) : 29 - 34
  • [27] New treatment for chronic lymphocytic leukemia
    Herold, T.
    Nitschmann, S.
    von Bergwelt, M.
    INTERNIST, 2020, 61 (01): : 110 - 112
  • [28] New agents in chronic lymphocytic leukemia
    Robak T.
    Current Treatment Options in Oncology, 2006, 7 (3) : 200 - 212
  • [29] Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia
    Chen, Shih-Shih
    Raval, Aparna
    Johnson, Amy J.
    Hertlein, Erin
    Liu, Te-Hui
    Jin, Victor X.
    Sherman, Mara H.
    Liu, Shu-Jun
    Dawson, David W.
    Williams, Katie E.
    Lanasa, Mark
    Liyanarachchi, Sandya
    Lin, Thomas S.
    Marcucci, Guido
    Pekarsky, Yuri
    Davuluri, Ramana
    Croce, Carlo M.
    Guttridge, Denis C.
    Teitell, Michael A.
    Byrd, John C.
    Plass, Christoph
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (32) : 13433 - 13438
  • [30] Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study
    Autore, Francesco
    Innocenti, Idanna
    Reda, Gianluigi
    Visentin, Andrea
    Vitale, Candida
    Piciocchi, Alfonso
    Fresa, Alberto
    Leone, Monica M. A.
    Farina, Lucia
    Quaresmini, Giulia
    Barate, Claudia
    Giordano, Annamaria
    Ferrari, Angela
    Angeletti, Ilaria
    De Paolis, Maria Rosaria
    Malerba, Lara
    Chiurazzi, Federico
    Loseto, Giacomo
    Catania, Gioacchino
    Sportoletti, Paolo
    Scortechini, Ilaria
    Moia, Riccardo
    Gentile, Massimo
    Rigolin, Gian Matteo
    Mattiello, Veronica
    Gattei, Valter
    Coscia, Marta
    Trentin, Livio
    Foa, Robin
    Cuneo, Antonio
    Laurenti, Luca
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (05) : 877 - 883